Lugano, Switzerland, 20 March 2025 – The European Lung Cancer Congress 2025 is the event dedicated to the prevention, diagnosis, and management of thoracic malignancies. Renowned experts from around the globe will convene to present the latest research in the field, offering their insights on, among others, screening and early detection of thoracic tumours, molecular characterisation of lung cancer, advancements in immunology and targeted therapies, and the evolving role of multidisciplinary decision-making in lung cancer.

The event will take place in Paris between 26-29 March and will be live streamed on the Virtual Congress Platform.

Programme picks

• New results on the long-term anti-tumour activity of immunotherapy combined with chemotherapy in various non-small cell lung cancer settings.

• Related content: 189MO, 186O, 11MO, 190P

• Novel data on the efficacy of subcutaneous over intravenous immunotherapies in treating NSCLC, emphasizing the benefits for both patients and healthcare professionals.

• Related content: 8MO, 33P, 58P

• Findings to extend treatment in EGFR-mutant advanced non-small cell lung cancer: from chemo-sparing strategies after disease progression to reducing adverse events in combination treatments.

• Related Content 9MO, 10MO

• Insights on availability of and accessibility to molecular testing in Europe and beyond, and on how to optimise testing to address the issue of lung cancer patients being treated without biomarker results.

• Related content: 401P, 101P; session on 27 March, 10:15 - 11:45 CET

• New therapeutic strategies for non-small cell lung cancer with specific genetic mutations after first line of treatment and advancements in actionable genomic alterations.

• Related Content: 2O, 3O, 4O; session on 26 March, 16:45 –18:15 CET

• Insights on the role of AI in lung cancer imaging, response assessment, radiation treatment planning and computational pathology

• Related Content: 357P, session on 27 March, 14:00-15:30 CET

Award lecture

• “HHH: History, Histopathology & Hyperbole. Lung cancer pathology comes of age” by Keith Kerr, recipient of the Heine H. Hansen Award, 26 March 2025, 13:50-14:30 CET

Keynote lecture

• “Less is more: De-escalation strategies in patient management and clinical trials” by Benjamin Besse, Fri, 28 March 2025, 14:00-14:30 CET

The abstracts will be published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.

Press accreditation
Press representatives working for recognised outlets interested in obtaining information and reporting on cancer issues are welcome to report on ELCC upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for ELCC 2025. To apply for press accreditation, please fill out the form available here. Please be kindly informed that onsite press accreditation will not be available.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).